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Abstract: 
 
Patients with stable ischemic heart disease (SIHD) require appropriate diagnosis, risk 
assessment, guideline-directed medical therapy, treatment, and follow up. The 2012 American 
College of Cardiology Foundation/American Heart Association guideline for the diagnosis and 
management of patients with SIHD assists nurse practitioners in the care of these patients. 
Knowledge of the treatments and the evidence supporting their use is essential to reduce 
morbidity and mortality in patients with SIHD. 
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Article:  
 
Ischemic heart disease (IHD), also called coronary heart disease or coronary artery disease, 
makes up more than half of all cardiovascular events in men and women younger than 75.1 The 
lifetime risk of developing IHD after age 40 is about 1 in 2 for men and 1 in 3 for women.1 The 
incidence of IHD in women lags behind men by 10 years for total disease and by 20 years for 
serious clinical events (eg, myocardial infarction [MI] and sudden cardiac death).1 Since 1968, 
deaths from IHD have declined as a result of medical and surgical treatments along with 
reduction in modifiable risk factors.1 
 
In 2012, the American College of Cardiology Foundation (ACCF)/American Heart Association 
(AHA) Task Force on Practice Guidelines, along with several other partnering associations, 
published a guideline for the diagnosis and management of adult patients with stable IHD 
(SIHD).2 The aim of this brief article is to review the 2012 guideline, placing emphasis on how 
nurse practitioners (NPs) can use these recommendations to manage patients with SIHD. 
Information from related research and guideline statements will also be included, as appropriate. 
 
 
 
Definition of IHD 
 
IHD is defined as the presence of atherosclerotic plaques in 1 or more of the major coronary 
arteries that supply blood to the heart muscle.3 Ischemia refers to an imbalance between 
myocardial oxygen supply and demand that is most commonly caused by plaques that impede 
blood flow to tissue distal to the stenosis.3 Angina pectoris, or angina for short, is the most 
common symptom of ischemia that occurs when oxygen demand exceeds oxygen supply.3 Stable 
angina, a manifestation of SIHD, is frequently described as retrosternal or substernal chest 
pressure that is typically precipitated by physical or emotional stress, is relieved by rest or 
sublingual nitroglycerin, and has a predictable pattern.3 
 
However, NPs need to be aware that, although resolution of symptoms with sublingual 
nitroglycerin (tablets or spray) heightens the clinician's suspicion for angina, esophageal spasm is 
described similarly by some patients and is also relieved by nitroglycerin. Furthermore, some 
patients experience atypical symptoms, such as dyspnea, fatigue, jaw or neck pain, nausea, or 
recurrent belching with exertion rather than chest discomfort. These symptoms are referred to as 
the patient's anginal equivalent (also known as ischemic equivalent).4 
 
Application of the Guidelines 
 
The 2012 guideline applies to patients with stable known or suspected IHD, including those with 
new-onset chest pain that are deemed to have low-risk unstable angina (UA). The classification 
of low-risk UA applies to individuals who are younger than 70, with symptoms of pain or 
discomfort during exertion lasting less than 20 minutes that does not rapidly accelerate, with a 
normal (or unchanged) 12-lead electrocardiogram (ECG), and no elevation of cardiac 
enzymes.2 Thus, recommendations for treatment from the 2012 guideline on SIHD do not apply 
to those with intermediate or high-risk UA or to those with an evolving MI, collectively known 
as acute coronary syndromes (ACS). 
 
Diagnosis 
 
Patients who present with chest pain or other symptoms suggestive of ischemia but are not 
known to have IHD should undergo a thorough history and physical examination to determine 
the probability of heart disease.2 As part of this assessment, NPs need to distinguish if the 
patient's symptoms are consistent with stable angina or low-risk UA, as opposed to intermediate 
or high-risk UA or an evolving MI (as discussed above). Assessment for the presence of risk 
factors for atherosclerosis should be performed at the initial presentation. Refer to Table 1 for a 
list of risk factors.5 
 
According to the guideline, a resting 12-lead ECG is recommended for all adults with 
nontraumatic chest pain or other symptoms suggesting ischemia. However, most patients will 
require further testing to confirm the diagnosis of IHD.2 If, during the evaluation, the patient has 
active symptoms or symptoms consistent with an ACS event, more immediate aggressive 
treatment is required (ie, aspirin and sublingual nitroglycerin administration, unless 
contraindicated, 12-lead ECG, and transportation to the nearest hospital).2 
 
Table 1. Major Risk Factors for Ischemic Heart Disease 
• Family history defined as cardiovascular disease in a male first-degree relative younger than 55 
or female first-degree relative younger than 65 
• Cigarette smoking 
• Diabetes mellitus 
• Dyslipidemia: elevated total or low-density lipoprotein cholesterol; high-density lipoprotein 
cholesterol 
• Hypertension 
• Physical inactivity 
• Obesity (body mass index ≥ 30 kg/m2) 
• Low fruit and vegetable consumption 
• Alcohol overconsumption 
• Men older than 45 and women older than 55 
Data from Chobanian et al.5 
 
Noninvasive Versus Invasive Diagnostic Testing 
 
The 2012 guideline recommends that patients with suspected ischemia (who are considered at 
low-risk) undergo noninvasive testing via stress testing.2 Factors that determine the initial choice 
for stress testing include the interpretability of the resting ECG, the patient's physical 
functioning, the pretest probability of IHD, and the availability of appropriate technology in the 
facility.2 
 
According to the guideline, a standard exercise stress test (exercise treadmill) is the first choice 
to diagnose IHD in patients who have an interpretable ECG (a normal baseline ECG) and are 
able to exercise at least 4 metabolic equivalents (equivalent to engaging in moderate activities 
such as climbing stairs, vacuuming, walking 3-3.5 mph, or heavy gardening).2 In patients who 
can exercise but have an abnormal resting ECG (eg, left ventricular [LV] hypertrophy, digitalis 
effect, or other reasons for ST-segment deviation at baseline), an exercise stress test with nuclear 
myocardial perfusion imaging or echocardiography is recommended to improve detectability of 
IHD.2 
 
If patients are unable to exercise, a pharmacologic stress is recommended.2 Coronary 
angiography, the gold standard for diagnosing IHD, is recommended for patients whose 
noninvasive testing indicates a high likelihood of severe IHD and when the benefits exceed 
risk.2 Those patients need a diagnostic angiography, unless third party payers require 
noninvasive testing first. 
 
The guideline also recommends Doppler echocardiography to assess resting left ventricular 
(systolic and diastolic function) and evaluation for abnormalities of myocardium, heart valves, or 
pericardium in patients with known or suspected IHD, a prior MI, pathological Q waves, 
symptoms or signs suggestive of heart failure (HF), complex ventricular arrhythmias, or an 
undiagnosed heart murmur.2 In addition, coronary angiography is also a reasonable option to 
assess risk in patients with depressed left ventricular function (ejection fraction [EF] < 50%) to 
evaluate the etiology of the HF.2 
 
SIHD Management 
 
Management of SIHD includes medical relief of symptoms and for secondary prevention of MI 
or death, patient education, risk factor modification, and revascularization, when 
indicated.3 Goals for treating SIHD include symptomatic relief (decrease the severity and 
frequency of angina symptoms), an increase in functional capacity and longevity, and a reduction 
in the incidence of ACS.2,3 
 
Pharmacotherapy for Symptom Relief 
 
Therapies to treat angina symptoms are directed toward improving the imbalance of oxygen 
supply and demand.2,6 Traditionally, anti-ischemic medications, such as beta-blockers, calcium 
channel blockers, and nitrates, have been directed at improving symptoms.2,6 Beta-blockers are 
the cornerstone of therapy for angina and are prescribed as first-line therapy for symptom relief 
in patients with SIHD, especially those with a history of MI.2 
 
Beta-blockers antagonize catecholamine-mediated stimulation of β1 and β2 receptors, lowering 
heart rate, decreasing contractility, and decreasing myocardial oxygen demand.6By lowering 
heart rate, beta-blockers lengthen diastole, consequently increasing coronary blood flow.6 In 
addition, beta-blockers are effective for the treatment of hypertension, arrhythmias, post-MI 
angina, and anxiety-induced anginal symptoms and have been shown to reduce mortality in 
patients with HF.2,6 However, it should be noted that only certain beta-blockers are approved by 
the Food and Drug Administration to treat chronic HF, including bisoprolol, carvedilol, and 
metoprolol. 
 
Major adverse effects of beta-blockers include hypotension, bradycardia, heart block, 
bronchospasm, and worsening HF.6 Other potential adverse effects include fatigue, depression, 
and sexual dysfunction.6 However, NPs need to keep in mind that beta-blockers, like other 
medications that are known to improve symptoms and survival, should not be withheld because 
of concerns of sexual side effects by the patient or the provider.7In fact, only about 3-5 patients 
per 1,000 have sexual side effects from beta-blockers.7 If, however, beta-blocker therapy causes 
erectile dysfunction, the patient may be converted to nebivolol, unless the patient has HF 
(a contraindication).7 
 
Finally, NPs should be mindful that abrupt withdrawal of beta-blockers may increase the 
frequency and severity of angina; thus, if discontinued, the drug should be tapered over several 
days to weeks.6 
 
Calcium channel blockers (CCBs) are reasonable options for symptom relief if a beta-blockers 
are contraindicated, poorly tolerated, or as an add-on agent if symptoms persist.2CCBs inhibit 
calcium ion movement into vascular smooth muscle and cardiac cells, resulting in blocking the 
calcium-dependent process leading to contraction.6 They reduce oxygen demand by causing 
systemic vasodilation and decreasing afterload.6 CCBs can also increase myocardial oxygen 
supply by dilating the coronary arteries.6 
 
Nondihydropyridine CCBs (eg, verapamil and diltiazem) have the additional ability to slow 
sinoatrial (SA) and atrioventricular (AV) node conduction, decreasing heart rate.6 Thus, they 
should be used cautiously when given in combination with other agents with negative 
chronotropic properties (eg, beta-blockers, digoxin).6 Dihydropyridine CCBs (eg, amlodipine, 
felodipine) do not inhibit SA and AV node conduction, so the antianginal mechanism of action is 
primarily from vasodilation.6 All CCBs, however, should be used cautiously in patients with 
severe ventricular dysfunction because of possible negative inotropic effects.6 
 
Organic nitrates have a well-established role in pharmacotherapy for angina. The major 
mechanism of action is to relax vascular smooth muscle, which reduces preload, afterload, and 
decreasing oxygen demand.3,6 Sublingual nitroglycerin is commonly used to treat acute angina 
symptoms and can be taken prophylactically during exertion known to produce angina.2,6 Long-
acting nitrates can be used for long-term prophylaxis in combination with beta-blockers or 
CCBs.2,6 Long-acting nitrates are available in both oral and transdermal formulations for chronic 
use. 
 
A major limitation of nitrate therapy is the development of tolerance with continuous use, 
regardless of route.6 Tolerance may occur within 24 hours of continuous exposure to the 
nitrate.6 To avoid tolerance and maintain antianginal properties of nitrates, it is recommended 
that a daily nitrate-free interval (NFI) of a minimum 8 hours and perhaps 12 hours be 
provided.6 The NFI is most commonly scheduled during the night when angina is unlikely to 
occur.6 Monotherapy with nitrates is not recommended because of reflex sympathetic stimulation 
from venodilation, and patients are not protected during the NFI.6 
 
Ranolazine, a relatively new medication, is indicated as an add-on agent to beta-blockers and 
CCBs for stable angina.2 It may also be considered for patients who are on CCB but unable to 
tolerate beta-blockers, yet still have angina. Ranolazine has a unique mechanism of action that is 
not completely understood.2,6 It is thought to inhibit the late inward sodium current during 
systole, which leads to reductions in intracellular calcium accumulation, left ventricular wall 
tension, and oxygen consumption.6 It has a neutral effect to oxygen supply and 
demand; antianginal properties do not affect heart rate, blood pressure, contractility, or coronary 
blood flow.3,6 
 
However, ranolazine may cause QT prolongation and is contraindicated with concurrent QT-
prolonging drugs or pre-existing prolonged QT.6 The medication also has several drug 
interactions and should be avoided with concurrent use of strong CYP3A4 inhibitors 
(ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, saquinavir, nefazodone) because 
of the potential for QT prolongation.2,6 In addition, the dose of ranolazine should be reduced if 
given in combination with moderate CYP3A4 inhibitors (diltiazem, verapamil, erythromycin, 
fluconazole), P-gp inhibitors (cyclosporine), P-gp or metabolized by CYP2DE agents (digoxin). 
See the packet insert for further details. 
 
Pharmacotherapy for Secondary Prevention 
 
Optimal medical management in patients with SIHD requires more than therapy for angina 
symptoms. Specific medical therapy aimed at secondary prevention includes the use of aspirin 75 
to 162 mg daily, in the absence of contraindications.2,8 According to the 2012 guideline, 
clopidogrel is a reasonable option when aspirin is contraindicated.2 
 
Beta-blocker therapy should be started and continued for 3 years in all patients with normal LV 
function after an MI or ACS.2 Beta-blockers should also be used in those with LV systolic 
dysfunction (EF ≤ 40%), unless contraindicated.2 
 
Currently, the optimal duration of beta-blocker therapy after MI is unknown. In the past it was 
thought that beta-blocker therapy should be continued indefinitely. However, the 2011 AHA 
Secondary Prevention Guideline was one of the first AHA guidelines to specify a time period for 
beta-blocker therapy (3 years).8 Beyond 3 years is optional if the patient is symptom free and has 
not had a subsequent MI or ACS event. In fact, a recent observational study of 5,000 patients 
with ST-segment elevation MI treated with primary percutaneous coronary intervention (PCI) 
found that adjusted mortality rates did not differ based on whether the patients were on beta-
blocker therapy or not.9 In subgroup analyses, the high-risk patients (those with HF associated 
with their MI) had a mortality benefit if beta-blockers were administered.9 
 
Angiotensin-converting enzyme (ACE) inhibitors should also be prescribed in all patients with 
SIHD who have hypertension, diabetes, LVEF ≤ 40%, or chronic kidney disease, unless 
contraindicated.2 Angiotensin-receptor blockers are recommended for patients intolerant of ACE 
inhibitors.2 An annual influenza vaccine is also recommended for patients with SIHD.2 In 
addition, according to the Centers for Disease Control and Prevention, all adults older than 65 
with chronic heart disease should receive a pneumococcal polysaccharide (PPSV23) vaccine.10 
 
Pharmocotherapies to Avoid 
 
Several pharmacotherapies are not recommended for the intent of reducing the risk of an MI or 
death. For example, hormone therapy has failed to demonstrate a reduction in the risk for IHD in 
postmenopausal women, thus should not be used.2,8,11 In addition, antioxidants (vitamin C, 
vitamin E, beta carotene), treatment for elevated homocysteine (folate, vitamin B6, and vitamin 
B12), chelation therapy, and certain dietary supplements (garlic, coenzyme Q10, selenium, 
chromium) are not recommended to reduce cardiovascular risk or improve clinical outcome and 
thus should not be used as primary or secondary prevention of IHD.2,8 
 
Patient Education 
 
Patients with SIHD should be provided individualized education that teaches them about heart-
healthy living, self-monitoring skills, and what action to take if symptoms worsen.2Self-
monitoring skills include knowing how to pace their activities and set goals based on the impact 
of stress, anxiety, or depression on symptoms. Patients should know the common symptoms of 
stress and depression and how to manage those in an effort to minimize angina caused by 
emotional stress.2 
 
Patients should also be assisted in developing an action plan for what to do if they experience 
recurrent angina symptoms. The plan should include advising them to stop their activity any time 
symptoms occur, take a sublingual nitroglycerin as prescribed (unless contraindicated), and, if 
symptoms continue, call emergency medical services (EMS). However, there is variation for 
when to call EMS. For example, some patients are instructed to call EMS if symptoms persist 5 
minutes after the first nitroglycerin; others are instructed to take up to 3 nitroglycerin doses, 5 
minutes apart, before calling EMS. This decision is individualized, based on past anginal 
episodes and the patient's response to nitroglycerin use. 
 
In addition to individualized teaching by the NP, there are many ways to offer patient (and 
family) education. One of the most effective ways is to make referrals to community resources 
(eg, cardiac rehabilitation programs, support groups, or other educational programs). To be 
highly effective in helping patients recover physically from a cardiac event, cardiac rehabilitation 
programs also provide a venue for safe exercise along with a comprehensive patient education 
program for patients with SIHD. However, despite proven benefits, many patients with SIHD are 
not routinely referred for structured cardiac rehabilitation programs or secondary prevention 
programs.12 
 
Patient education may be provided in varied formats (eg, written materials, Web-based, face-to-
face) and should consider culture and literacy levels. For example, innovative strategies such as 
mobile phone interventions or telemonitoring may be used with appropriate patients. A recent 
systematic analysis concluded that the use of smartphone applications and text messaging 
interventions, combined with education or additional interventions to promote weight reduction 
and physical activity, have found a beneficial impact to outcomes and cost.13 
 
Combined with patient education, it is also important for NPs to maintain regular communication 
with their patients to provide a feedback loop. NPs should work closely with patients to set 
treatment goals, discuss potential barriers to lifestyle measures or other medical therapy, and 
solicit ideas from patients for overcoming nonadherence. NPs are ideally positioned to develop 
relationships, assess readiness for lifestyle change, and empower patients to find ways to 
improve outcomes. For example, motivational interviewing can be used to help patients increase 
their confidence in making behavior changes, especially if they are ambivalent.14 
 
Risk Factor Modification 
 
The 2012 guideline recommends guideline-directed medical therapy for modifiable risk factors 
aimed at preventing cardiovascular events. NPs should address risk factor modification 
at each patient encounter. Lifestyle modifications coexist within the same realm 
as pharmacotherapy for secondary prevention and may help lower doses of certain medications. 
Furthermore, some medications that patients take for comorbid conditions may negatively 
influence risk factors (eg, progestins, corticosteroids). 
 
According to the guideline, risk-factor modification includes management of lipids, blood 
pressure, and diabetes; addressing physical activity and weight management; counseling on 
smoking cessation, alcohol use, and avoidance of pollution; and the management of 
psychological factors (eg, depression).2 Refer to Table 2. 
 
NPs should ask patients about smoking status and advise each tobacco user to quit at each visit. 
For those considering cessation, developing a plan that includes pharmacotherapy or referral to a 
formal program has been shown to be more effective in long-term cessation.2 Some patients and 
providers may be concerned about using nicotine replacement therapy in patients with SIHD, 
fearing these agents may trigger ischemia. However, a randomized, controlled trial of 10 
Veterans Affairs medical centers, including 584 patients with at least 1 cardiovascular diagnosis, 
found no difference in the primary endpoints (death, MI, cardiac arrest, and hospital admission 
for cardiovascular disease) at 14 weeks between the nicotine and placebo groups. Overall, the 
risks of nicotine replacement are lower than those of smoking and the benefits outweigh the risk 
of continuing to smoke.15 
 
Table 2. Guideline-directed Medical Therapy for Stable Ischemic Heart Disease 
• Dietary modifications: reduce saturated fat (< 7% of total calories), trans fatty acids (< 1% of total 
calories), and cholesterol intake (< 200 mg/day); reduce sodium intake; increase fruits, vegetables, 
low-fat dairy. All incorporating cultural and ethnic preferences 
• Physical activity: 30-60 minutes of moderate aerobic activity on 5-7 days per week supplemented 
by an increase in daily activities; medically supervised programs for at-risk patients with a first-time 
diagnosis 
• Moderate to high dose statin, unless contraindicated 
• Body mass index between 18.5 and 24.9 kg/m2 and waist circumference < 102 cm (40 inches) in 
men and < 88 cm (35) inches in women 
• Blood pressure goal < 140/90 mmHg 
• Hemoglobin A1c < 7% for most individuals with diabetes 
• Smoking cessation; avoid environmental tobacco exposure (secondhand smoke and air pollution) 
• Screening for depression and increased stress 
• Alcohol intake: no more than 1 serving/day for nonpregnant women or low weight men; no more 
than 1-2 servings/day for men. 1 serving = 4 oz of wine, 12 oz of beer, 1 oz spirits 
Data from Fihn et al.2 
 
All patients with SIHD should have a goal of attaining 30-60 minutes of moderate-intensity 
aerobic activity at least 5 days/week.2 Brisk walking supplemented with walking breaks at work, 
gardening, household work, and taking the stairs when possible should be encouraged. Patients 
should be reminded that the activity does not need to occur at 1 sitting; it may be cumulative. 
 
Weight management is one of the toughest risk factors to address in caring for those with SIHD. 
Per the guideline, the waist circumference should be measured during each visit on the patient's 
side horizontally at the iliac crest and should be ≤ 35 inches (89 cm) for women and ≤ 40 inches 
(102 cm) for men.2,16 If a patient is overweight or obese, the initial goal for weight loss should be 
to decrease weight by 5%-10%, followed by further weight loss over 6-12 months until they 
meet and maintain a body mass index goal between 18.5-24.9 kg/m2.2,16 
 
NPs should counsel patients about appropriate recommendations for alcohol use. No patient 
should be encouraged to ingest alcohol to improve cardiovascular health. However, if a patient 
with SIHD elects to use alcohol, women should have no more than 1 serving per day; men no 
more than 2 servings per day. The guideline provides a more stringent recommendation for 
serving size for wine or liquor as compared to other guidelines (ie, JNC-7).5 One serving is 
considered 4 ounces of wine, 12 ounces of beer, or 1 ounce of spirits. Contraindications for 
alcohol include pregnancy, history of alcohol abuse or dependence, or liver impairment/disease.2 
 
Revascularization 
 
When optimal medical therapy fails or if extensive atherosclerosis is present, PCI with stenting 
(bare metal or drug eluding) or coronary artery bypass grafting (CABG) surgery may be 
performed to relieve symptoms and restore blood flow to the coronary arteries.2The choice 
between these options is based on disease complexity, culprit lesion locations, LV function, and 
ischemia associated arrhythmias.2 However, results from the COURAGE trial suggest that there 
is no reduction in major adverse cardiac events or mortality with PCI compared to optimal 
medical therapy alone in patients with SIHD.17 
 
Patient Follow-Up 
 
Patients with SIHD should receive follow up on at least an annual basis to assess for the 
following: presence of symptoms and functional ability, surveillance for complications such as 
HF or arrhythmias, monitoring of risk factors, and adherence to recommended lifestyle changes 
and medical therapy.2 Patients who present with new or worsening symptoms of HF or evidence 
of an MI (by history or ECG) should undergo assessment of LV function by echocardiography or 
radionuclide imaging.2 Although, in the absence of symptoms or a chance in clinical status, 
assessment of LV function is not recommended.2 However, a resting 12-lead ECG is reasonable 
in patients with stable symptoms.2 It is also reasonable to screen periodically for comorbidities, 
such as diabetes mellitus, depression, and kidney disease.2 
 
Similar to initial noninvasive testing, exercise testing is recommended in patients with known 
IHD with new, recurrent, or worsening symptoms not consistent with ACS, UA, or MI.2 Similar 
factors determine the mode of testing recommended in known IHD, including exercise ability 
and ECG interpretability. 
 
Special Circumstances 
 
NPs should also educate patients with SIHD about recommendations for sexual activity. 
According to the AHA 2012 Scientific Statement on Sexual Activity and Cardiovascular 
Disease,7 sexual activity is reasonable for patients with SIHD who are at low risk for 
cardiovascular complications and are experiencing no more than mild angina. A good rule of 
thumb for NPs to use when considering if sexual activity is reasonable for a patient is to ask if 
the patient can exercise > 3-5 metabolic equivalents without angina, excessive dyspnea, ischemic 
ST-segment changes, or arrhythmias.7 However, patients with unstable, decompensated, or 
severe symptomatic IHD should defer sexual activity until they are stabilized.7 Likewise, if the 
patient experiences symptoms that are precipitated by sexual activity, they should refrain from 
intercourse until optimally managed. 
 
For patients recovering from an uncomplicated MI, PCI, or bypass surgery and having no 
recurrent symptoms during mild-moderate physical activity, a period of 1 or more weeks should 
pass before they engage in sexual activity.7 For patients of unknown risk, exercise stress testing 
is reasonable to determine exercise capacity and development of symptoms, ischemia, or 
arrhythmias.7 For additional information related to sexual side effects from medications and how 
to treat them, NPs may refer to the 2012 Statement on Sexual Activity and Cardiovascular 
Disease.7 
 
Conclusion 
 
With the use of national guidelines to treat patients with SIHD, NPs are ideally positioned to 
evaluate symptoms, conduct risk assessment, promote required lifestyle modifications, prescribe 
guideline-directed medical therapy, and partner with patients to address barriers to adherence. In 
addition to referring patients to a structured cardiac rehabilitation programs, NPs can personally 
educate patients about ways to adopt a heart-healthy lifestyle, be engaged in self-monitoring of 
symptoms and other comorbid conditions, and live a life at their fullest functional capacity. 
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